Most Read Articles
Roshini Claire Anthony, 4 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 5 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, 3 days ago
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Haematological abnormalities bear increased infection risk in rheumatoid arthritis

09 Oct 2019

Rheumatoid arthritis (RA) patients with comorbid anaemia and lymphopenia are at heightened risk of developing common infections, as study has found.

The study included 6,591 individuals (mean age 58.7 years; 67.5 percent female) with newly diagnosed RA. Anaemia was prevalent at diagnosis, detected in 1,066 patients (16.2 percent). Other haematological abnormalities found included neutropenia (n=38; 0.6 percent) and lymphopenia (n=97; 1.5 percent).

RA patients with anaemia and lymphopenia were older than the entire population. Furthermore, those with anaemia tended to be male and had greater comorbidity.

Over a median follow-up of 2.2 years, infection events were recorded in 658 RA patients in the anaemia group, 19 in the neutropenia group, 73 in the lymphopenia group and 3,506 in the no-haematological abnormality group. Crude rates of infection were 181.2, 151.8, 256.4 and 172.0 per 1,000 person-years, respectively.

Lymphopenia and anaemia were associated with heightened infection risk (hazard ratios [HRs], 1.18, 95 percent CI, 1.08–1.29 and 1.37, 1.08–1.73, respectively). There was no evidence of association noted for neutropenia (HR, 0.94, 0.60–1.47).

On further analysis, pneumonia occurred more commonly in RA patients than those without the autoimmune disorder. Influenza vaccination had a protective effect on influenza-like illness in RA patients.

The findings suggest that haematological markers may be used to identify RA patients who might benefit from targeted counselling to stress the importance of early presentation if symptoms of infection develop, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 5 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, 3 days ago
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).